USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PULMOKINE, INC.
Address:
PULMOKINE, INC.
68 QUEEN ANNE DR
SLINGERLANDS, NY 12159-9385
Phone:
N/A
URL:
EIN:
126141519
DUNS:
808479906
Number of Employees:
4
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $887,597.00 3
SBIR Phase II $2,267,504.00 1

Award List:

A novel JAK inhibitor for the treatment of pulmonary arterial hypertension

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$311,629.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined JAK1/JAK2 inhibitor or more selective JAK2 inhibitor for PAH that will be delivered by inhalation.… More

A PDGFR inhibitor for the treatment of pulmonary arterial hypertension

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$351,008.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel highly selective platelet derived growth factor receptor (P DGFR) inhibitor for PAH that will be… More

An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,267,504.00
Agency:
HHS
Principal Investigator:
Lawrence S. Zisman – 518-573-8315
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with… More

IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$224,960.00
Agency:
HHS
Principal Investigator:
Lawrence Zisman – 518-573-8315
Abstract:
Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC HEALTH RELEVANCE